Company intelligence / Profile preview

HOB Biotech Group

Ownership: Private
Employees: ~58
Development stage: Commercial

Overview

HOB Biotech is a leading Chinese in vitro diagnostics company specializing in allergy and autoimmune disease testing. It has commercialized multiple diagnostic platforms globally and is the market leader in China’s allergy/autoimmune diagnostics segment. The company also has a biopharmaceutical R&D arm with five major drug candidates targeting oncology and autoimmunity—two are in Phase III trials as of late 2023.

Therapeutic areas: OncologyImmunology
Modalities: Diagnostic deviceImmunoassay (including Enzyme-linked immunosorbent assay, Chemiluminescent immunoassay, Line immunoassay)Monoclonal antibody (for some pipeline therapeutics)
Industry: Biotech

Partnerships

Notable partnerships with pharmaceutical firms and research institutions are referenced but not named specifically.Jinhe Capital is an investor.

Beyond the preview

Go deeper on HOB Biotech Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HOB Biotech Group.